Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus - Wikidata - wikimedia - TriplyDB

Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus

Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus

http://www.wikidata.org/entity/Q34887952

about

Present and future in the treatment of diabetic kidney disease Is fenofibrate a reasonable treatment for diabetic microvascular disease?The effects of glucose-lowering therapies on diabetic kidney disease The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease.The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.Zinc status in type 2 diabetic patients: relation to the progression of diabetic nephropathy.New insight into the molecular drug target of diabetic nephropathy.Epidemiology of micro- and macrovascular complications of type 2 diabetes in Korea.Diabetic nephropathy in Africa: A systematic review.Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat Dialysis and fatigue: implications for nurses--a case study analysis Foot insensitivity is associated with renal function decline in patients with type 2 diabetes: a cohort study.An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study miRNAs in Urine Extracellular Vesicles as Predictors of Early-Stage Diabetic Nephropathy DiabCare survey of diabetes management and complications in the Gulf countries.Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Antidiabetic and Antinephritic Activities of Aqueous Extract of Cordyceps militaris Fruit Body in Diet-Streptozotocin-Induced Diabetic Sprague Dawley Rats Impact of Type 2 Diabetes on Impaired Kidney Function in Sub-Saharan African Populations.The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial Renal Protective Role of Xiexin Decoction with Multiple Active Ingredients Involves Inhibition of Inflammation through Downregulation of the Nuclear Factor-κB Pathway in Diabetic Rats.Additive Effect of Qidan Dihuang Grain, a Traditional Chinese Medicine, and Angiotensin Receptor Blockers on Albuminuria Levels in Patients with Diabetic Nephropathy: A Randomized, Parallel-Controlled Trial.Obstructive sleep apnea and diabetic nephropathy: a cohort study.GSK-3β function in bone regulates skeletal development, whole-body metabolism, and male life span Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review.Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Individualized glycaemic targets and pharmacotherapy in type 2 diabetes.Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.Influence of vanadium-organic ligands treatment on selected metal levels in kidneys of STZ rats Association of Auricular Reflective Points and Status of Type 2 Diabetes Mellitus: A Matched Case-Control Study.Diabetic Nephropathy: a Tangled Web to Unweave.Personalized Diabetes Management: Moving from Algorithmic to Individualized Therapy.The renal archaeologist: digging for clues in archived tissues to understand diabetic kidney disease.Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.

P2860

Q26864133-5615C778-41EE-4916-A809-E9413D655AE5 Q30372692-0229EFEE-033E-4661-BEE4-FD0C5E8D9016 Q33583220-900DD4E9-3FB7-4F7C-991A-61442D851404 Q33698333-4786C010-AFE1-412A-A656-772647830746 Q34503796-7DB0274E-3F07-4BBC-9845-9FDA67DB0B09 Q34891146-60AF7F9C-B8BE-46EE-A194-C667F63F5561 Q34909787-4834CF36-ACEF-45F2-8CC7-CC07EFF60C8A Q35125585-9ACDD28D-D73C-4C7D-92B6-154A1469410E Q35661422-974D0E79-BC5A-4318-AFD5-86A336D7C177 Q35691399-1A2C70DF-4EB2-429C-B31B-AE50AA774310 Q35768430-A9C0F137-B63B-4939-BC86-FA5BCE993090 Q36149351-014C825E-4AB6-412D-BF28-44E09A88DD64 Q36201450-57194971-5859-4C93-A663-09D556245111 Q36232508-6098669D-1A68-40B5-A65C-2FC97D77A54E Q36560252-A9B5D7A7-CD79-441E-B7F5-45E0D6EE1D6A Q36569046-2501C808-8833-4E9D-86FD-E7DBBF1E0D72 Q36687510-66555560-D25C-437A-AC9B-6E56C5C2390F Q36868370-F054B0B8-4764-4B88-A0CE-493956D0151B Q36883337-A7A396B5-2EC6-4B6C-B758-4E3E9D2653E5 Q36909985-A0CFDDDA-2FF2-4A2D-BCEC-F07B9E29A655 Q36946421-2F08A6D0-7887-42BC-B7A2-DAC19C42CB43 Q37019265-8CBC4639-64A4-4AB5-9CE9-CDD1434F70BA Q37019804-059AB7CB-FBAD-41F1-85A5-8D032D5E4A53 Q37027123-E471AF0D-1526-47FB-93D8-5E68120BAB46 Q37278124-873D5C8A-C16F-4FB2-BF3D-9FCE75BED16A Q37317729-3892E206-4974-4AD3-B48E-6CC6869DB853 Q37554671-597D63A5-BFB0-462B-8986-2CFE8AF32CBD Q38002007-95CACD46-ED21-48E6-8EF5-E2358E2A26D4 Q38012068-BBD4E237-B534-4632-8D0F-EC972E99396B Q38109751-49002FF0-DF2C-4796-A59B-D5A09A84F642 Q38231646-120F41A8-1973-47CE-A835-D9378AA33413 Q38497122-71083E32-1360-4250-80DF-B85D23EB0D7B Q39855313-A4FBA863-1124-4E5B-A859-F08E818B0D3F Q41191031-C4BD6517-1327-4AC1-961B-1B4102537F46 Q41564974-F5DB4604-7652-4649-9A97-A53844CF1079 Q41993558-9ED62CDA-1ABB-4252-984A-E8B57D4B20F3 Q42138665-BF40C7F5-9CC3-4628-853A-8C41870A015A Q43156352-151F8982-E7A0-4ACC-ABB8-13B4920F23BE Q43470326-94141F44-2323-41EA-9940-34EF81809098 Q44211603-2A731141-321B-42A6-AC29-F9E98E6CBD74

P2860

Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus

http://www.wikidata.org/entity/Q34887952

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@ast

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@en

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@nl

type

label

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@ast

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@en

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@nl

prefLabel

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@ast

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@en

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@nl

P1433

Q34887952-1734B1B8-C53B-4AFC-941C-898C89C55ADF

P1476

Q34887952-DFC993FE-83A2-4264-A83C-ACD809BACF09

P2093

Q34887952-24155861-E9B1-44B3-9D8D-11A507536BB1

P2860

Q34887952-025D2C26-DDB1-4883-92B0-C2AB328410C1

Q34887952-0D350CA3-077E-40AF-9A5B-8DB5E76A9D09

Q34887952-0DE8AA93-D5F6-4C2E-BB29-03884BBCCB08

Q34887952-13C4D35D-0AFE-4776-BEFE-2C36E0412B89

Q34887952-15EDE794-4554-4C6F-976B-C2DBA2108E7D

Q34887952-1958C093-38D7-43E4-B37C-A192A10541D8

Q34887952-1B82EA40-1F50-4662-BD8C-E38CB779E8D5

Q34887952-2188AC48-3361-4402-9F32-E9700B4C151F

Q34887952-21BA3F51-8B9E-4425-9F0E-20FC15A09BF4

Q34887952-21D68622-C4AD-4977-AD9F-44E0587DE314

P304

Q34887952-B7DD2570-F8C3-4735-AB33-FD6E10824A8C

P31

Q34887952-42E322E3-CF6C-4A76-9192-F27165487851

P356

Q34887952-22D34D82-838A-4F3B-883D-E79662E24CE6

P407

Q34887952-ABF5FE43-9A07-4186-B224-97D38C9AA4F9

P433

Q34887952-48AA64BF-52C4-4786-AFF7-9FC488324B90

P478

Q34887952-944A725E-9ECC-4570-8AD0-83208791D12F

P577

Q34887952-89EE2FA7-2D1C-45F5-BCC6-1A27524A7850

P5875

Q34887952-B93E397C-C465-4E74-A461-E626F303560A

P698

Q34887952-2F38AD53-074D-43A7-BE95-CE3C52070E34

P921

Q34887952-89B2027D-375C-4536-8D65-903C7A9C9A9F

P932

Q34887952-90F26C20-69F0-4762-B0AC-9E1708D3A208

P356

P1433

Mayo Clinic Proceedings

P1476

Recognition, pathogenesis, and ...... with type 2 diabetes mellitus

@en

P2093

George L Bakris

http://www.w3.org/2001/XMLSchema#string

P2860

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

A new equation to estimate glomerular filtration rate

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

P304

444-456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4065/MCP.2010.0713

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51088139

http://www.w3.org/2001/XMLSchema#string

P698

21531886

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3084647

http://www.w3.org/2001/XMLSchema#string